Department of Paediatric Oncology, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands.
Department of Paediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
Eur J Cancer. 2015 Jul;51(11):1424-34. doi: 10.1016/j.ejca.2015.02.010. Epub 2015 May 18.
Radiotherapy is a well-known cause of adverse events (AEs). To reduce AEs, an innovative local treatment was developed in Amsterdam: Ablative surgery, MOuld brachytherapy and surgical REconstruction (AMORE).
(1) to determine the prevalence of AEs in HNRMS survivors and (2) to compare AEs between survivors treated with the international standard: external beam radiotherapy (EBRT-based: London) and survivors treated with AMORE if feasible, otherwise EBRT (AMORE-based: Amsterdam).
All HNRMS survivors, treated in London or Amsterdam between January 1990 and December 2010 (n = 153), and alive ⩾ 2 years post-treatment were eligible (n = 113). A predefined list of AEs was assessed in a multidisciplinary clinic and graded according to the Common Terminology Criteria for Adverse Events.
Eighty HNRMS survivors attended the clinic (median follow-up 10.5 years); 63% experienced ⩾ 1 severe or disabling event, and 76% had ⩾ 5 AEs (any grade). Survivors with EBRT-based treatment were, after adjustment for site, age at diagnosis, and follow-up duration, at increased risk to develop any grade 3/4 event or ⩾ 5 AEs (any grade) compared with survivors with AMORE-based treatments (p = 0.032 and 0.01, respectively). Five year overall survival (source population) after EBRT-based treatment was 75.0%, after AMORE-based treatment 76.9%, p = 0.56.
This study may serve as a baseline inventory and can be used in future studies for prospective assessments of AEs following the introduction of novel local treatment modalities. AMORE-based local treatment resulted in similar overall survival and a reduction of AEs secondary to local treatment.
放射治疗是不良事件(AE)的已知原因。为了减少 AE,阿姆斯特丹开发了一种创新的局部治疗方法:消融手术、模具近距离放射治疗和手术重建(AMORE)。
(1)确定 HNRMS 幸存者中 AE 的发生率;(2)比较接受国际标准治疗的幸存者(基于伦敦外照射放射治疗的 EBRT)和接受 AMORE 治疗的幸存者(可行时采用 AMORE,否则采用 EBRT)之间的 AE。
所有于 1990 年 1 月至 2010 年 12 月期间在伦敦或阿姆斯特丹接受治疗、治疗后 ⩾ 2 年存活的 HNRMS 幸存者(n = 153)符合条件(n = 113)。在多学科诊所中评估了一组预先确定的 AE,并根据常见不良事件术语标准进行了分级。
80 名 HNRMS 幸存者参加了诊所(中位随访 10.5 年);63%经历过 ⩾ 1 次严重或致残事件,76%有 ⩾ 5 种 AE(任何等级)。与接受 AMORE 治疗的幸存者相比,接受 EBRT 治疗的幸存者在调整了部位、诊断时年龄和随访时间后,发生任何 3/4 级事件或 ⩾ 5 种 AE(任何等级)的风险增加(分别为 p = 0.032 和 0.01)。EBRT 治疗后的 5 年总生存率(源人群)为 75.0%,AMORE 治疗后为 76.9%,p = 0.56。
本研究可作为基线清单,并可在未来的前瞻性研究中用于评估新型局部治疗方法后 AE 的发生情况。基于 AMORE 的局部治疗导致相似的总生存率,并减少了局部治疗引起的 AE。